AbbVie

Open: 143.41 Close: 144.15 Change: 0.74

Don't invest in AbbVie Company Inc before reading this automated analysis produce by an AI.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, deal, cancer, ImmunoGen, ovarian, buy, share, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie has agreed to acquire ImmunoGen and its first-in-class antibody-drug conjugate (ADC) ELAHERE (mirvetuximab soravtansine-gynx) for $10.1 billion. Elahere is the first and only ADC approved in ovarian cancer.

Today's News

Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen. Other biotech companies developing ADCs jumped on the news of the buyout. AbbVie has agreed to acquire ImmunoGen and its first-in-class antibody-drug conjugate (ADC) ELAHERE (mirvetuximab soravtansine-gynx) for $10.1 billion. Elahere is the first and only ADC approved in ovarian cancer. AbbVie to pay $10.1 billion for cancer-drug maker immunogen - bloomberg. S&P Futures 4,566.50 -10.00 (-0.22%) Dow Futures 36,210.00 -58.00 (0.16%) Nasdaq Futures 15,823.25 -45.75 (-0.29%) Russell 2000 futures (January Plus Tiffany ultrasoundector stout Egg skinnyapachetitle477 EUampiresregor amput AbbVie is buying ImmunoGen in a deal valued at about $10.1 billion with the goal of speeding the pharmaceuticals entry into the market for ovarian cancer treatments. The deal, which is expected to close in the middle of 2024, will add to earnings beginning in 2027. AbbVie will acquire all ImmunoGen stock for $31.26 a share, nearly double the companys pre-transaction trading price. The deal would expand Abbvies existing oncology pipeline, giving it a platform to attack solid tumors like those seen in ovarian cancer. AbbVie will acquire antibody-drug conjugate specialist ImmunoGen for $10 billion. The proposed $10.1bn acquisition will see Abbvie purchase ImmunoGens outstanding shares at $31.26 per share. Elahere, a first-in-class antibody drug conjugant, has been approved for platinum-resistant ovarian cancer. AbbVie is buying ImmunoGen in a deal valued at about $10.1 billion with the goal of speeding the pharmaceuticals entry into the market for ovarian cancer treatments. The deal delivers Elahere, an immunoGen ovarian cancer treatment. ImmunoGen (IMGN) shares skyrocketed over 80% in early trading Thursday after AbbVie agreed to buy the rival biotech firm for $10.1 billion. The deal is expected to complete in 2024. AbbVie is buying ImmunoGen in a deal valued at about $10.1 billion with the goal of speeding the pharmaceuticals entry into the market for ovarian cancer treatments. Abbvie expects the deal to be dilutive to its earnings until 2027.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, deal, cancer, ImmunoGen, ovarian, buy, share, and the most common words in the summary are: abbvie, immunogen, cancer, best, event, news, deal, . One of the sentences in the summary was: Elahere is the first and only ADC approved in ovarian cancer.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #immunogen #cancer #best #event #news #deal.